View : 395 Download: 0

EGFR inhibitor suppresses tumor growth by blocking lipid uptake and cholesterol synthesis in non-small cell lung cancer

Title
EGFR inhibitor suppresses tumor growth by blocking lipid uptake and cholesterol synthesis in non-small cell lung cancer
Authors
Rhie B.-H.; Woo S.H.; Kim H.-Y.; Karapurkar J.K.; Jo W.-J.; Kim J.; Kim D.H.; Choi M.J.; Park Y.J.; Hong Y.; Hong S.-H.; Ramakrishna S.; Kim K.-S.
Ewha Authors
김재상
SCOPUS Author ID
김재상scopus
Issue Date
2025
Journal Title
Biochimica et Biophysica Acta - Molecular Basis of Disease
ISSN
0925-4439JCR Link
Citation
Biochimica et Biophysica Acta - Molecular Basis of Disease vol. 1871, no. 7
Keywords
Cholesterol biosynthesis; Epidermal growth factor receptor; Kinase activity; Lipid uptake; Low-density lipoprotein receptor; Non-small cell lung cancer; Tumor growth
Indexed
SCIE; SCOPUS WOS scopus
Document Type
Article
Abstract
Accelerated cholesterol and lipid metabolism are hallmarks of non-small cell lung cancer (NSCLC). Recently, epidermal growth factor receptor (EGFR) signaling has been shown to regulate de novo cholesterol synthesis and low-density lipoprotein receptor (LDLR) expression through SREBP-1-dependent pathways. This suggests that targeting EGFR signaling in cholesterol metabolism might provide a new therapeutic strategy for NSCLC. In this study, we demonstrated that AX-0085, a small-molecule drug, significantly inhibits EGFR kinase activity and subsequently suppresses cholesterol and lipid metabolism in NSCLC. Transcriptomic analysis showed that cholesterol and lipid metabolism-related transcripts were significantly downregulated in AX-0085-treated NSCLC cells compared to the mock control. In addition, AX-0085 downregulates EGF signaling-dependent SREBP1-mediated cholesterol biosynthesis-related enzymes and LDLR in NSCLC. Moreover, AX-0085 dramatically reduced proliferation, colony-forming ability, and migration in NSCLC cells by blocking EGFR signaling. Furthermore, treatment with AX-0085 decreased both tumor size and volume in the LLC-xenograft model. These results demonstrate that AX-0085 effectively suppresses cholesterol metabolism in NSCLC cells by inhibiting EGF-mediated SREBP1 signaling, suggesting a potential therapeutic strategy targeting cholesterol metabolism in NSCLC. © 2025 Elsevier B.V.
DOI
10.1016/j.bbadis.2025.167957
Appears in Collections:
자연과학대학 > 생명과학전공 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE